SBBP News and Press, Strongbridge Biopharma plc From 10/22/20

DUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...

Gainers:  Ebang International (NASDAQ: EBON ) +42% . More news on: Ebang International Holdings Inc., Cardiff Oncology, Inc., Herman Miller, Inc., Stocks on the move, , Read more ...

Strongbridge Biopharma (NASDAQ: SBBP )   -16%  after pricing $25M share offering. More news on: Strongbridge Biopharma plc, NuCana plc, Dave & Buster's Entertainment, Inc., Stocks on the move, , Read more ...

Strongbridge Biopharma (NASDAQ: SBBP ) has priced its public offering of ~11.1M ordinary shares at $2.25/share for total gross proceeds of ~$25M. More news on: Strongbridge Biopharma plc, Healthcare stocks news, , Read more ...

DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced ...

DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced ...

Our analysis concludes Strongbridge Biopharma PLC ( SBBP ) is materially undervalued now that SBBP has reported positive Phase 3 topline date for Recorlev. This is primarily because Recorlev should (soon if not now) be worth at least 2 (but probably 3) times its estimated peak annual sales of ...

Gainers:  Luby's (NYSE: LUB ) +102% . More news on: Luby's, Inc., Nikola Corporation, Albireo Pharma, Inc., Stocks on the move, , Read more ...

Strongbridge Biopharma (NASDAQ: SBBP ) announces positive results from a 44-subject Phase 3 clinical trial, LOGICS , evaluating Recorlev (levoketoconazole) in patients with endogenous Cushing's syndrome, a metabolic disorder characterized by the excess production of the hormone cortisol...

~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV ® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome; To View the Complete Earlier Announcement, Visit the Company’s Website ~...